Literature DB >> 19818373

Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.

Swati Bhowmick1, Tuhina Mazumdar, Roma Sinha, Nahid Ali.   

Abstract

Liposomes have been widely exploited as antigen delivery systems for a variety of diseases including leishmaniasis. These vesicles can be prepared in various ways which may affect the immunogenicity of the encapsulated antigens. In this study we compared the vaccine potentiality of three cationic formulations with Leishmania donovani promastigote membrane antigens (LAg) and the best vesicle was evaluated for long-term protection against experimental visceral leishmaniasis. We immunized mice with LAg encapsulated in multilamellar vesicles (MLV), dehydration-rehydration vesicles (DRV) and reverse-phase evaporation vesicles (REV) and challenged them with parasites ten days after vaccination. LAg in MLV or DRV induced almost complete protection, while LAg alone or entrapped in REV exhibited partial resistance. Protection observed with antigen incorporated MLV or DRV was predominantly Th1 as evidenced by elicitation of significantly high DTH, IgG2a antibodies and IFN-gamma. MLV encapsulated LAg demonstrated durable cell-mediated immunity and mice challenged ten weeks after vaccination could also resist experimental challenge strongly. Field trials of L. donovani vaccine were unsatisfactory mainly due to lack of an appropriate adjuvant. Cationic MLV when used as adjuvant with protein antigens induced sustained Th1 immunity. Adjuvant potential of cationic MLV can be utilized to design subunit vaccines. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818373     DOI: 10.1016/j.jconrel.2009.09.018

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  23 in total

1.  Cationic liposomal sodium stibogluconate (SSG), a potent therapeutic tool for treatment of infection by SSG-sensitive and -resistant Leishmania donovani.

Authors:  Roma Sinha; Jayeeta Roychoudhury; Partha Palit; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2014-11-03       Impact factor: 5.191

Review 2.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

3.  Novel antigen delivery technologies: a review.

Authors:  Deepika Jain; Vikas Jain; Ranjit Singh
Journal:  Drug Deliv Transl Res       Date:  2011-04       Impact factor: 4.617

4.  Negatively charged liposomes show potent adjuvant activity when simply admixed with protein antigens.

Authors:  Nijaporn Yanasarn; Brian R Sloat; Zhengrong Cui
Journal:  Mol Pharm       Date:  2011-06-07       Impact factor: 4.939

Review 5.  Liposomal adjuvant development for leishmaniasis vaccines.

Authors:  Anis Askarizadeh; Mahmoud Reza Jaafari; Ali Khamesipour; Ali Badiee
Journal:  Ther Adv Vaccines       Date:  2017-11-15

Review 6.  Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.

Authors:  John C Kraft; Jennifer P Freeling; Ziyao Wang; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2013-11-25       Impact factor: 3.534

Review 7.  Targeted immunomodulation using antigen-conjugated nanoparticles.

Authors:  Derrick P McCarthy; Zoe N Hunter; Bryce Chackerian; Lonnie D Shea; Stephen D Miller
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2014-03-10

Review 8.  Social and Economic Burden of Human Leishmaniasis.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Am J Trop Med Hyg       Date:  2016-01-19       Impact factor: 2.345

9.  Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.

Authors:  Rajesh Ravindran; Sudipta Bhowmick; Amrita Das; Nahid Ali
Journal:  BMC Microbiol       Date:  2010-06-24       Impact factor: 3.605

10.  Liposomes and nanotechnology in drug development: focus on oncotargets.

Authors:  Tomohiro Kozako; Naomichi Arima; Makoto Yoshimitsu; Shin-Ichro Honda; Shinji Soeda
Journal:  Int J Nanomedicine       Date:  2012-09-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.